Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.15 USD

14.15
961,268

+0.34 (2.46%)

Updated Jul 25, 2024 10:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Emergent's Vaccine Portfolio Aids Growth Amid Competition

Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.

Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates

Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.

Emergent Biosolutions (EBS) Q2 Earnings Lag Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25.00% and 14.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Emergent Biosolutions (EBS) Q2 Earnings Expected to Decline

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

Why Is Emergent Biosolutions (EBS) Down 23.4% Since Last Earnings Report?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

New Strong Sell Stocks for May 3rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Emergent Biosolutions (EBS) Reports Q1 Loss, Misses Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -200.00% and -6.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Reports Next Week: Wall Street Expects Earnings Growth

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates

Emergent (EBS) rides high on both earnings and a revenue beat in Q4.

Emergent Biosolutions (EBS) Q4 Earnings and Revenues Surpass Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 22.95% and 0.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Emergent Biosolutions (EBS) Q4 Earnings Expected to Decline

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed

Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint

Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.

Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

Emergent Biosolutions (EBS) Q3 Earnings and Revenues Lag Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -11.29% and -7.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q3 Earnings: What's in Store?

Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.